Status:
RECRUITING
Pharmacogenomics-Supported Psychotropic Prescribing Trial
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
University of Calgary
Shared Health Manitoba
Conditions:
Mental Disorder
Pharmacogenetics
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.
Detailed Description
Background and Rationale: Pharmacogenomic (PGx) testing utilizes genetic information as a surrogate marker of a person's ability to process and react to drugs. This information can be used to inform m...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated
- The treating clinician thinks PGx testing can benefit and refers the patient to the study
Exclusion
- Unwillingness to donate saliva samples for genetic analysis
- History of liver or bone marrow (hematopoietic cell) transplantation
- PGx testing results are already available
- No personal health identification number (PHIN) is available
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06929533
Start Date
July 1 2025
End Date
December 31 2030
Last Update
September 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shared Health Facilities
Winnipeg, Manitoba, Canada, R3C 3H8
2
University of Manitoba College of Pharmacy
Winnipeg, Manitoba, Canada, R3E 0T5